GANTANOL-DS
LOE ApproachingNDAORALTABLET
Approved
Aug 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTANOL-DS is an oral tablet antibiotic approved by Roche in 1965. The drug is a sulfamethoxazole-based sulfonamide antibiotic used to treat bacterial infections. It represents a foundational class of antimicrobial therapy with decades of clinical use.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), brand teams are likely focused on managed decline and maximizing remaining market share through niche positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GANTANOL-DS offers minimal career growth opportunity as the product is in decline phase with no linked job postings. Career progression is constrained by lack of innovation, limited market expansion, and organizational focus on wind-down rather than growth initiatives.
Brand ManagerProduct Manager
Worked on GANTANOL-DS at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.